Thymoglobulin25 mg/10 ml

Thymoglobulin is a polyclonal antibody preparation with established and guideline-supported uses in transplantation and hematology:

• Prevention of acute rejection in renal transplant patients, used as part of an immunosuppressive regimen in conjunction with corticosteroids and other immunosuppressants (established/approved use).
• Treatment of acute renal transplant rejection in conjunction with concomitant immunosuppression, typically when rejection is steroid-resistant (established/approved use).
• Treatment of moderate to severe aplastic anemia, particularly in patients who are not candidates for bone marrow/stem cell transplantation, usually combined with cyclosporine (established/approved use, product-specific).
• Off-label uses (guideline-supported in specialist practice but not universally labeled): induction immunosuppression and graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation, and induction therapy in other solid organ transplants (e.g., heart, liver, lung, pancreas).

Thymoglobulin must be prescribed and administered only by physicians experienced in immunosuppressive therapy and management of transplant/hematology patients.

Each vial of Anti-Thymocyte Globulin contains purified, pasteurized/gamma-globulin fraction of antiserum raised in an animal (typically rabbit or horse, depending on the specific commercial product) immunized with human thymocytes. The product is standardized for immunosuppressive antibody activity and supplied as a lyophilized powder or concentrated solution for intravenous infusion after dilution.

Thymoglobulin is a polyclonal immunoglobulin preparation obtained by immunizing an animal (rabbit or equine, depending on manufacturer) against human thymocytes (T-lymphocyte precursor cells). The resulting purified antibodies target and deplete circulating T-lymphocytes, producing profound immunosuppression. It is administered as a slow intravenous infusion in a hospital or specialized transplant/hematology unit under continuous medical supervision, never as a self-administered outpatient medicine.

Boxed Warning

Thymoglobulin should be administered only by physicians experienced in immunosuppressive therapy, in a facility adequately equipped and staffed to manage severe hypersensitivity and anaphylactic reactions, with the patient under close clinical monitoring throughout the infusion.

Thymoglobulin belongs to the class of polyclonal antibody immunosuppressants (lymphocyte-depleting agents), used to prevent or treat cell-mediated rejection of transplanted organs and to suppress abnormal immune-mediated bone marrow destruction in aplastic anemia.

Mechanism of Action

Anti-Thymocyte Globulin contains cytotoxic antibodies directed against antigens present on human T-lymphocytes (such as CD2, CD3, CD4, CD8, CD11a, CD18, CD25, and HLA class I and II molecules). Binding of these antibodies to circulating T-lymphocytes causes cell depletion through complement-dependent lysis, opsonization and phagocytic clearance, and induction of apoptosis, as well as modulation of T-cell activation markers. The resulting profound reduction in circulating T-lymphocytes suppresses cell-mediated immune responses responsible for graft rejection and, in aplastic anemia, is believed to reduce T-cell-mediated suppression of hematopoietic stem cells.

Pharmacokinetics

After intravenous infusion, Anti-Thymocyte Globulin is distributed in plasma and lymphoid tissue. Its biological effect (T-cell depletion) persists well beyond measurable serum antibody levels, with a terminal half-life ranging from several days to a few weeks depending on the specific product and patient factors. Elimination occurs gradually via the reticuloendothelial system.

Thymoglobulin is administered only as a slow intravenous infusion, diluted in normal saline or dextrose solution, through an in-line filter, preferably via a central venous catheter or high-flow peripheral vein, in a hospital setting with resuscitation facilities and continuous monitoring available. It must never be given as a rapid IV push, intramuscular, or subcutaneous injection.

Thymoglobulin has clinically significant interactions related to its profound immunosuppressive effect:

• Other immunosuppressants (corticosteroids, calcineurin inhibitors such as cyclosporine/tacrolimus, mycophenolate, azathioprine, other biologic immunosuppressants): concurrent use is often intentional as part of a combination regimen, but the combined immunosuppressive burden substantially increases the risk of serious infection and malignancy; doses require careful coordination and monitoring.
• Live or live-attenuated vaccines: should be avoided during and for a prolonged period after Thymoglobulin therapy because of the risk of disseminated vaccine-strain infection due to profound immunosuppression.
• Other agents causing myelosuppression: concurrent use may increase the risk of significant leukopenia and thrombocytopenia; blood counts should be monitored closely.

Adverse effects of Thymoglobulin are frequent, particularly with the first infusion, and require close monitoring:

• Infusion-related/cytokine-release reactions: fever, chills, rigors, hypotension or hypertension, dyspnea, nausea, and in severe cases anaphylaxis (see Precautions).
• Hematologic: thrombocytopenia and leukopenia (common, usually reversible; requires regular blood count monitoring).
• Serum sickness: fever, rash, arthralgia, and lymphadenopathy occurring days to weeks after administration, related to the foreign (animal) protein content.
• Infections: increased susceptibility to bacterial, viral (including CMV and other opportunistic viral reactivation), fungal, and other opportunistic infections due to immunosuppression.
• Malignancy: increased long-term risk of malignancy, including post-transplant lymphoproliferative disease (PTLD), with prolonged or repeated immunosuppression.
• Other: local injection-site reactions, headache, myalgia, diarrhea, and elevated liver enzymes have been reported.

Adequate and well-controlled studies of Thymoglobulin in pregnant women are not available. Thymoglobulin should be used during pregnancy only if clearly needed and the potential benefit to the mother justifies the potential risk to the fetus; use should be under close specialist supervision, typically in the context of a life- or graft-saving indication where alternatives are limited. It is not known whether Thymoglobulin is excreted in human breast milk; because of the potential for serious adverse effects in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother, in consultation with a physician.

Thymoglobulin carries important precautions beyond its boxed warning:

• Anaphylaxis and severe hypersensitivity/cytokine-release reactions can occur, especially with the first dose; premedication, slow controlled infusion rates, and close monitoring with resuscitation equipment immediately available are required. The infusion should be stopped immediately if severe reaction signs occur.
• Increased risk of serious and opportunistic infections due to profound T-cell depletion; patients should be monitored for signs of infection during and after therapy.
• Increased risk of malignancy, including post-transplant lymphoproliferative disease, with prolonged or repeated courses.
• Thrombocytopenia and leukopenia are common; complete blood counts should be monitored regularly during therapy, with dose adjustment or interruption if counts fall significantly.
• Serum sickness may occur days to weeks after treatment; patients should be counseled to report fever, rash, or joint pain after discharge.
• Thymoglobulin must be administered only in an inpatient specialized transplant or hematology setting equipped to manage severe reactions; it is not suitable for outpatient self-administration.
• Live vaccines should be avoided during and for a period after therapy (see Interactions).

There is limited specific information on overdose with Thymoglobulin because it is administered only under direct medical supervision with calculated, weight-based dosing. Excessive dosing would be expected to increase the severity of infusion reactions, immunosuppression-related infection risk, and hematologic toxicity (thrombocytopenia, leukopenia). If overdose is suspected, the infusion should be stopped immediately, the patient should receive close monitoring and supportive care in a hospital setting, and emergency medical services or the treating specialist team should be contacted immediately. There is no specific antidote.

Store vials in a refrigerator (2°C to 8°C); do not freeze. Protect from light. Diluted infusion solutions should be used within the time specified by the manufacturer and product labeling. Keep out of reach of children. This product is administered only by healthcare professionals in a clinical setting.

Renal/Hepatic Impairment: No formal dose adjustment guidelines are well established for renal or hepatic impairment; Thymoglobulin is used with caution and close monitoring in these populations, as they are often the very patients (transplant recipients) receiving therapy.

Elderly: Limited specific data; use with caution given the higher baseline risk of infection and comorbidities in elderly patients.

Pediatric: See Pediatric Uses.

Pregnancy/Lactation: See Pregnancy and Lactation.

Treatment duration with Thymoglobulin is a defined, short course (typically 4 to 14 days depending on indication and specific product), determined by the treating specialist based on indication, clinical response, and laboratory monitoring (blood counts, graft function). It is not intended for continuous or open-ended use.

Lyophilized (powder) formulations of Thymoglobulin must be reconstituted with the diluent specified by the manufacturer (typically sterile water for injection), gently swirled (not shaken) to avoid foaming, and then further diluted in normal saline or dextrose solution for intravenous infusion, per the specific product's package insert.

Polyclonal antibody immunosuppressant; lymphocyte-depleting agent

Anti-Thymocyte Globulin binds to multiple antigens on human T-lymphocytes, causing depletion of circulating T-cells via complement-mediated lysis, opsonization/phagocytosis, and apoptosis, thereby suppressing the cell-mediated immune response responsible for transplant rejection and contributing to immune modulation in aplastic anemia.

The safety and efficacy of Thymoglobulin in pediatric patients have not been as extensively established through large controlled trials as in adults; however, it is used off-label in specialist pediatric transplant and hematology centers for aplastic anemia and transplant rejection prophylaxis/treatment, with weight-based dosing extrapolated from adult regimens and adjusted per specific product labeling and institutional protocol. Use in children should be limited to specialized pediatric transplant/hematology units with appropriate monitoring capability.